These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7857597)

  • 1. Monoamine activity reflected in urine of young patients with obsessive compulsive disorder, psychosis with and without reality distortion and healthy subjects: an explorative analysis.
    Oades RD; Röpcke B; Eggers C
    J Neural Transm Gen Sect; 1994; 96(2):143-59. PubMed ID: 7857597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relations of clinical features, subgroups and medication to serum monoamines in schizophrenia.
    Oades RD; Klimke A; Henning U; Rao ML
    Hum Psychopharmacol; 2002 Jan; 17(1):15-27. PubMed ID: 12404703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics.
    Hsiao JK; Colison J; Bartko JJ; Doran AR; Konicki PE; Potter WZ; Pickar D
    Arch Gen Psychiatry; 1993 Aug; 50(8):606-14. PubMed ID: 7688209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subclinical polydipsia and polyuria in young patients with schizophrenia or obsessive-compulsive disorder vs normal controls.
    Oades RD; Daniels R
    Prog Neuropsychopharmacol Biol Psychiatry; 1999 Nov; 23(8):1329-44. PubMed ID: 10631761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment.
    Kahn RS; Davidson M; Knott P; Stern RG; Apter S; Davis KL
    Arch Gen Psychiatry; 1993 Aug; 50(8):599-605. PubMed ID: 7688208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute effects of neuroleptics on unmedicated schizophrenic patients and controls.
    Miller AL; Maas JW; Contreras S; Seleshi E; True JE; Bowden C; Castiglioni J
    Biol Psychiatry; 1993 Aug; 34(3):178-87. PubMed ID: 8104509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis.
    Mazure CM; Nelson JC; Jatlow PI; Bowers MB
    Biol Psychiatry; 1991 Sep; 30(5):475-82. PubMed ID: 1932395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conditioned blocking in patients with paranoid, non-paranoid psychosis or obsessive compulsive disorder: associations with symptoms, personality and monoamine metabolism.
    Oades RD; Zimmermann B; Eggers C
    J Psychiatr Res; 1996; 30(5):369-90. PubMed ID: 8923341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No major influence of regular tobacco smoking on cerebrospinal fluid monoamine metabolite concentrations in patients with psychotic disorder and healthy individuals.
    Hjärpe J; Söderman E; Andreou D; Sedvall GC; Agartz I; Jönsson EG
    Psychiatry Res; 2018 May; 263():30-34. PubMed ID: 29482043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the central dopaminergic index of plasma HVA in schizophrenia.
    Amin F; Davidson M; Kahn RS; Schmeidler J; Stern R; Knott PJ; Apter S
    Schizophr Bull; 1995; 21(1):53-66. PubMed ID: 7770741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma catecholamines and their metabolites in obsessive-compulsive disorder.
    Benkelfat C; Mefford IN; Masters CF; Nordahl TE; King AC; Cohen RM; Murphy DL
    Psychiatry Res; 1991 Jun; 37(3):321-31. PubMed ID: 1891512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of psychotic inpatients with high or low HVA levels at admission.
    Bowers MB
    Am J Psychiatry; 1991 Feb; 148(2):240-3. PubMed ID: 1670980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid monoamine metabolite concentrations as intermediate phenotypes between glutamate-related genes and psychosis.
    Andreou D; Söderman E; Axelsson T; Sedvall GC; Terenius L; Agartz I; Jönsson EG
    Psychiatry Res; 2015 Sep; 229(1-2):497-504. PubMed ID: 26142836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paranoid schizophrenics may not use irrelevant signals. The use of measures of blocking and of urinary dopamine.
    Oades RD; Bunk D; Eggers C
    Acta Paedopsychiatr; 1992; 55(3):183-4. PubMed ID: 1357915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lithium in combination with perphenazine: effect on plasma monoamine metabolites.
    Bowers MB; Mazure CM; Nelson JC; Jatlow PI
    Biol Psychiatry; 1992 Dec; 32(12):1102-7. PubMed ID: 1477190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoamines (serotonin and catecholamines) and their derivatives in infantile autism: age-related changes and drug effects.
    Martineau J; Barthélémy C; Jouve J; Muh JP; Lelord G
    Dev Med Child Neurol; 1992 Jul; 34(7):593-603. PubMed ID: 1380929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenylethylamine and monoamine metabolites in CSF of schizophrenics: effects of neuroleptic treatment.
    Beckmann H; Waldmeier P; Lauber J; Gattaz WF
    J Neural Transm; 1983; 57(1-2):103-10. PubMed ID: 6194254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of fenfluramine on plasma HVA in OCD.
    Hollander E; Stein DJ; Saoud JB; DeCaria CM; Cooper TB; Trungold S; Stanley M; Liebowitz MR
    Psychiatry Res; 1992 May; 42(2):185-8. PubMed ID: 1631253
    [No Abstract]   [Full Text] [Related]  

  • 19. Childhood obsessive-compulsive disorder presenting as schizophrenia spectrum disorders.
    Rodowski MF; Cagande CC; Riddle MA
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):395-401. PubMed ID: 18759651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary MHPG and HVA excretion in boys with attention deficit disorder and hyperactivity treated with d-amphetamine.
    Shekim WO; Javaid J; Davis JM; Bylund DB
    Biol Psychiatry; 1983 Jun; 18(6):707-14. PubMed ID: 6871304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.